S&P 500 7,723.39 ▲ 46.62 (+0.61%) DOW 52,389.06 ▲ 27.48 (+0.05%) NASDAQ 26,480.43 ▲ 311.05 (+1.19%) US Markets Closed â€ĸ 08:38 PM ET

XLO

Xilio Therapeutics, Inc.

Price Chart
Latest Quote

$8.01

+0.30 (+3.89%)
Current Price
Previous Close $7.71
Open $7.86
Day High $8.01
Day Low $7.17
Volume 27,920
Fetched: 2026-10-28T00:38:35
Stock Information
Shares Outstanding 6.58M
Total Debt $6.30M
Cash Equivalents $136.04M
Revenue $64.09M
Net Income $-21.83M
Sector Healthcare
Industry Biotechnology
Market Cap $52.71M
EPS (TTM) $-0.62
Exchange NCM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$-77.03M
Sales$64.09M
Income$-21.83M
Book/sh$10.98
Cash/sh$20.67
Employees76
Financial Ratios
Quick Ratio4.15
Current Ratio4.25
Debt/Eq8.72
Returns & Margins
ROA-13.61%
ROE-55.03%
Gross Margin83.16%
Operating Margin-18.68%
Profit Margin-34.06%
Ownership
Insider Ownership25.98%
Institutional Ownership49.44%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-13.81
P/S0.82
P/B0.73
Analyst Data
Recommendationstrong_buy
Target Price$18.00
Technical Indicators
SMA20$nan
SMA50$nan
SMA200$nan
RSI19.42
ATRnan
Shares Float3.40M
Short Float6.96%
Short Ratio38.99
Volatility-0.12
Rel Volume1.86
Performance History
Weeknan%
Monthnan%
Quarternan%
6 Monthsnan%
YTDnan%
Yearnan%
3 Yearsnan%
10 Yearsnan%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-10-27 $nan 27,920
2026-10-26 $7.31 33,500
2026-10-23 $7.57 16,300
2026-10-22 $8.03 15,400
2026-10-21 $8.43 36,300
2026-10-20 $8.54 13,500
2026-10-19 $8.33 11,500
2026-10-16 $8.55 29,600
2026-10-15 $9.02 10,400
2026-10-14 $8.90 12,400
2026-10-13 $9.22 18,100
2026-10-12 $9.07 8,400
2026-10-09 $9.05 5,500
2026-10-08 $9.01 20,800
2026-10-07 $9.01 900
2026-10-06 $9.00 6,200
2026-10-05 $9.11 7,200
2026-10-02 $9.01 7,400
2026-10-01 $8.91 12,900
2026-09-30 $9.05 5,400
2026-09-29 $8.94 3,100
2026-09-28 $9.05 11,100
About Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

📰 Latest News
No news articles available at the moment. Check back later for updates on XLO.
Period:
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Total Revenue $43,766,000 $6,344,000 $0 $0
Operating Revenue $43,766,000 $6,344,000 $0 $0
Expenses
Total Expenses $85,748,000 $65,989,000 $79,133,000 $89,149,000
Other Income Expense $6,946,000 $1,404,000 $2,729,000 $927,000
Other Non Operating Income Expenses $1,101,000 $2,341,000 $2,729,000 $927,000
Operating Expense $85,748,000 $65,989,000 $79,133,000 $89,149,000
General And Administrative Expense $29,709,000 $24,778,000 $26,997,000 $29,948,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-35,036,000 $-58,241,000 $-76,404,000 $-88,222,000
Normalized Income $-40,881,000 $-57,304,000 $-76,404,000 $-88,222,000
Net Income From Continuing And Discontinued Operation $-35,036,000 $-58,241,000 $-76,404,000 $-88,222,000
Total Operating Income As Reported $-41,982,000 $-60,582,000 $-79,133,000 $-89,149,000
Net Income Common Stockholders $-35,036,000 $-58,241,000 $-76,404,000 $-88,222,000
Net Income $-35,036,000 $-58,241,000 $-76,404,000 $-88,222,000
Net Income Including Noncontrolling Interests $-35,036,000 $-58,241,000 $-76,404,000 $-88,222,000
Net Income Continuous Operations $-35,036,000 $-58,241,000 $-76,404,000 $-88,222,000
Pretax Income $-35,036,000 $-58,241,000 $-76,404,000 $-88,222,000
Special Income Charges $0 $-937,000 $0 -
Operating Income $-41,982,000 $-59,645,000 $-79,133,000 $-89,149,000
Per Share
Diluted EPS $-4.19 $-15.26 $-38.92 $-45.08
Basic EPS $-4.19 $-15.26 $-38.92 $-45.08
Other
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-46,286,000 $-57,064,000 $-77,233,000 $-87,302,000
Total Unusual Items $5,845,000 $-937,000 $0 -
Total Unusual Items Excluding Goodwill $5,845,000 $-937,000 $0 -
Reconciled Depreciation $1,541,000 $1,644,000 $1,900,000 $1,847,000
EBITDA (Bullshit earnings) $-40,441,000 $-58,001,000 $-77,233,000 $-87,302,000
EBIT $-41,982,000 $-59,645,000 $-79,133,000 $-89,149,000
Diluted Average Shares $8,359,108 $3,822,244 $1,964,007 $1,956,577
Basic Average Shares $8,359,108 $3,822,244 $1,964,007 $1,956,577
Diluted NI Availto Com Stockholders $-35,036,000 $-58,241,000 $-76,404,000 $-88,222,000
Restructuring And Mergern Acquisition $0 $937,000 $0 -
Gain On Sale Of Security $5,845,000 - - -
Research And Development $56,039,000 $41,211,000 $52,136,000 $59,201,000
Selling General And Administration $29,709,000 $24,778,000 $26,997,000 $29,948,000
Other Gand A $13,388,000 $10,132,000 $11,170,000 $13,247,000
Salaries And Wages $16,321,000 $14,646,000 $15,827,000 $16,701,000
Fetched: 2026-10-22
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $35,273,000 $17,598,000 $36,827,000 $105,647,000
Total Assets $154,685,000 $71,075,000 $60,926,000 $139,165,000
Total Non Current Assets $9,658,000 $10,841,000 $12,799,000 $14,669,000
Other Non Current Assets $1,807,000 $1,782,000 $1,732,000 $1,829,000
Current Assets $145,027,000 $60,234,000 $48,127,000 $124,496,000
Other Current Assets $2,496,000 $4,943,000 $3,423,000 $4,111,000
Receivables $5,000,000 $0 - -
Other Receivables $5,000,000 - - -
Cash Cash Equivalents And Short Term Investments $137,531,000 $55,291,000 $44,704,000 $120,385,000
Cash And Cash Equivalents $137,531,000 $55,291,000 $44,704,000 $120,385,000
Prepaid Assets - - - $4,111,000
Debt
Total Debt $6,954,000 $8,142,000 $12,504,000 $19,939,000
Long Term Debt And Capital Lease Obligation $5,611,000 $6,954,000 $8,142,000 $12,354,000
Current Debt And Capital Lease Obligation $1,343,000 $1,188,000 $4,362,000 $7,585,000
Current Debt - - $3,315,000 $6,667,000
Other Current Borrowings - - $3,315,000 $6,667,000
Long Term Debt - - - $3,165,000
Liabilities
Total Liabilities Net Minority Interest $119,412,000 $53,477,000 $24,099,000 $33,518,000
Total Non Current Liabilities Net Minority Interest $63,139,000 $26,216,000 $8,142,000 $12,399,000
Other Non Current Liabilities $7,333,000 - - $45,000
Derivative Product Liabilities $29,560,000 $0 - -
Non Current Deferred Liabilities $20,635,000 $19,262,000 $0 -
Current Liabilities $56,273,000 $27,261,000 $15,957,000 $21,119,000
Current Deferred Liabilities $40,023,000 $13,518,000 $0 -
Payables And Accrued Expenses $9,174,000 $8,347,000 $6,857,000 $8,039,000
Payables $3,168,000 $2,574,000 $1,050,000 $3,125,000
Accounts Payable $3,168,000 $2,574,000 $1,050,000 $3,125,000
Other Current Liabilities - - $48,000 $82,000
Equity
Common Stock Equity $35,273,000 $17,598,000 $36,827,000 $105,647,000
Total Equity Gross Minority Interest $35,273,000 $17,598,000 $36,827,000 $105,647,000
Stockholders Equity $35,273,000 $17,598,000 $36,827,000 $105,647,000
Retained Earnings $-418,789,000 $-383,753,000 $-325,512,000 $-249,108,000
Other
Ordinary Shares Number $4,530,640 $3,268,340 $1,971,974 $1,958,960
Share Issued $4,530,640 $3,268,340 $1,971,974 $1,958,960
Tangible Book Value $35,273,000 $17,598,000 $36,827,000 $105,647,000
Invested Capital $35,273,000 $17,598,000 $40,142,000 $115,479,000
Working Capital $88,754,000 $32,973,000 $32,170,000 $103,377,000
Capital Lease Obligations $6,954,000 $8,142,000 $9,189,000 $10,107,000
Total Capitalization $35,273,000 $17,598,000 $36,827,000 $108,812,000
Additional Paid In Capital $454,062,000 $401,351,000 $362,336,000 $354,752,000
Capital Stock $0 $0 $3,000 $3,000
Common Stock $0 $0 $3,000 $3,000
Preferred Stock $0 $0 $0 $0
Non Current Deferred Revenue $20,635,000 $19,262,000 $0 -
Long Term Capital Lease Obligation $5,611,000 $6,954,000 $8,142,000 $9,189,000
Current Deferred Revenue $40,023,000 $13,518,000 $0 -
Current Capital Lease Obligation $1,343,000 $1,188,000 $1,047,000 $918,000
Pensionand Other Post Retirement Benefit Plans Current $5,733,000 $4,208,000 $4,690,000 $5,413,000
Current Accrued Expenses $6,006,000 $5,773,000 $5,807,000 $4,914,000
Net PPE $7,851,000 $9,059,000 $11,067,000 $12,840,000
Accumulated Depreciation $-8,753,000 $-7,427,000 $-5,861,000 $-4,418,000
Gross PPE $16,604,000 $16,486,000 $16,928,000 $17,258,000
Leases $5,124,000 $5,124,000 $5,124,000 $5,124,000
Construction In Progress $459,000 $0 $0 $98,000
Other Properties $10,340,000 $10,498,000 $10,940,000 $11,172,000
Machinery Furniture Equipment $681,000 $864,000 $864,000 $864,000
Properties $0 $0 $0 $0
Buildings And Improvements - $4,587,000 $5,125,000 -
Fetched: 2026-10-22
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-5,510,000 $-18,414,000 $-69,106,000 $-77,590,000
Operating Activities
Operating Cash Flow $-4,992,000 $-18,378,000 $-68,620,000 $-75,723,000
Cash Flow From Continuing Operating Activities $-4,992,000 $-18,378,000 $-68,620,000 $-75,723,000
Operating Gains Losses $-3,561,000 $3,000 $3,000 $1,000
Investing Activities
Capital Expenditure $-518,000 $-36,000 $-486,000 $-1,867,000
Investing Cash Flow $-518,000 $-36,000 $-486,000 $-1,867,000
Cash Flow From Continuing Investing Activities $-518,000 $-36,000 $-486,000 $-1,867,000
Financing Activities
Issuance Of Capital Stock $40,655,000 $6,825,000 $0 $0
Financing Cash Flow $87,775,000 $29,196,000 $-6,550,000 $-69,000
Cash Flow From Continuing Financing Activities $87,775,000 $29,196,000 $-6,550,000 $-69,000
Net Common Stock Issuance $40,655,000 $6,825,000 $0 $0
Common Stock Issuance $40,655,000 $6,825,000 $0 $0
Net Preferred Stock Issuance - - - $0
Preferred Stock Issuance - - - $0
Net Other Financing Charges - - - -
Other
Repayment Of Debt $0 $-3,382,000 $-6,752,000 $-85,000
Interest Paid Supplemental Data $0 $62,000 $573,000 $555,000
End Cash Position $139,338,000 $57,073,000 $46,291,000 $121,947,000
Beginning Cash Position $57,073,000 $46,291,000 $121,947,000 $199,606,000
Changes In Cash $82,265,000 $10,782,000 $-75,656,000 $-77,659,000
Proceeds From Stock Option Exercised $47,120,000 $25,753,000 $202,000 $16,000
Net Issuance Payments Of Debt $0 $-3,382,000 $-6,752,000 $-85,000
Net Long Term Debt Issuance $0 $-3,382,000 $-6,752,000 $-85,000
Long Term Debt Payments $0 $-3,382,000 $-6,752,000 $-85,000
Net PPE Purchase And Sale $-518,000 $-36,000 $-486,000 $-1,867,000
Purchase Of PPE $-518,000 $-36,000 $-486,000 $-1,867,000
Change In Working Capital $25,125,000 $31,782,000 $-1,658,000 $2,004,000
Change In Other Working Capital $27,877,000 $32,780,000 - -
Change In Payables And Accrued Expense $-827,000 $-17,000 $-1,888,000 $2,070,000
Change In Accrued Expense $-979,000 $-1,543,000 $175,000 $1,585,000
Change In Payable $152,000 $1,526,000 $-2,063,000 $485,000
Change In Account Payable $152,000 $1,526,000 $-2,063,000 $485,000
Change In Prepaid Assets $3,075,000 $-981,000 $688,000 $344,000
Change In Receivables $-5,000,000 $0 - -
Stock Based Compensation $6,939,000 $6,434,000 $7,382,000 $8,424,000
Depreciation Amortization Depletion $1,541,000 $1,644,000 $1,900,000 $1,847,000
Depreciation And Amortization $1,541,000 $1,644,000 $1,900,000 $1,847,000
Gain Loss On Investment Securities $-3,561,000 - - -
Gain Loss On Sale Of PPE $0 $3,000 $3,000 $1,000
Net Income From Continuing Operations $-35,036,000 $-58,241,000 $-76,404,000 $-88,222,000
Change In Other Current Liabilities - $-1,047,000 $-918,000 $-801,000
Change In Other Current Assets - $539,000 $460,000 $391,000
Other Non Cash Items - - $157,000 $223,000
Issuance Of Debt - - - $0
Long Term Debt Issuance - - - $0
Fetched: 2026-10-22